LRMR

Peers: DSGN LXEO SLDB RARE SRPT WVE DYN PEPG STOK ZVRA

| Held by: VTI IWM FESM VXF IWO VTWO DFAS IBB VHT IWC

Index	RUT
Market Cap	277.37M
Enterprise Value	126.06M
Income	-172.60M
Sales	0.00M
Book/sh	1.22
Cash/sh	1.50
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	71
IPO	Jun 19, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.19
P/C	1.77
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.70
Current Ratio	4.70
Debt/Eq	0.04
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.98
EPS next Y	-1.17
EPS next Q	-0.34
EPS this Y	39.62%
EPS next Y	14.62%
EPS next 5Y	38.33%
EPS past 3/5Y	-18.15% 8.74%
Sales past 3/5Y	- -
EPS Y/Y TTM	-27.00%
Sales Y/Y TTM	-
EPS Q/Q	23.18%
Sales Q/Q	-
Earnings	Aug 04 BMO
EPS/Sales Surpr.	21.36% -

Insider Own	54.01%
Insider Trans	0.09%
Inst Own	49.71%
Inst Trans	5.79%
ROA	-109.49%
ROE	-139.63%
ROIC	-131.62%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	9.17%
SMA50	-17.79%
SMA200	-29.97%
Trades

Shs Outstand	103.88M
Shs Float	48.00M
Short Float	30.55%
Short Ratio	11.24
Short Interest	14.66M
52W High	6.42 -58.41%
52W Low	1.91 39.43%
Volatility	8.51% 8.62%
ATR (14)	0.21
RSI (14)	49.40
Beta	0.70
Rel Volume	0.00
Avg Volume	1.30M
Volume	0

Perf Week	17.62%
Perf Month	-16.43%
Perf Quarter	-30.10%
Perf Half Y	-34.24%
Perf YTD	-29.92%
Perf Year	-38.05%
Perf 3Y	0.38%
Perf 5Y	-77.66%
Perf 10Y	-92.73%
Recom	1.10
Target Price	14.89
Prev Close	2.67
Price	2.67
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$14.89

Implied Upside

+457.7%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 14, 2026	Resumed	LLeerink Partners	Outperform	$13	+386.9%
Jul 02, 2026	Resumed	HH.C. Wainwright	Buy	$10	+274.5%
May 27, 2026	Initiated	JJP Morgan	Overweight	$9	+237.1%
Jan 29, 2025	Initiated	TTruist	Buy	$18	+574.2%
Oct 16, 2024	Initiated	OOppenheimer	Outperform	$26	+873.8%
Oct 03, 2024	Initiated	WWedbush	Outperform	$22	+724.0%
Oct 02, 2024	Initiated	HH.C. Wainwright	Buy	$15	+461.8%
Sep 04, 2024	Initiated	RRobert W. Baird	Outperform	$16	+499.3%
Apr 03, 2024	Initiated	LLeerink Partners	Outperform	$25	+836.3%
Nov 17, 2023	Upgrade	CCitigroup	Neutral → Buy	$4.50	+68.5%
Oct 19, 2022	Initiated	GGuggenheim	Buy	$12	+349.4%
Feb 15, 2022	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Feb 10, 2021	Initiated	JJMP Securities	Mkt Outperform
Feb 01, 2021	Initiated	WWilliam Blair	Outperform	$29	+986.1%

Sep-29-26 04:05PM	Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer (GlobeNewswire)
Aug-04-26 07:09AM	Larimar: Q2 Earnings Snapshot (Associated Press)
07:00AM	Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update (GlobeNewswire)
Jul-08-26 06:44PM	LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 (Stocktwits) +5.87% +14.40%
Jul-02-26 04:32PM	LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns (Stocktwits)
10:00AM	Loading…
Jun-29-26 10:00AM	Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) (InvestorsHub) -12.57%
09:02AM	Larimar's Rare Disease Push Just Hit A Key Inflection Point What Investors Need To Know (Stocktwits)
06:30AM	Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's Ataxia (GlobeNewswire)
Jun-26-26 04:05PM	Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire)
May-14-26 07:10AM	Larimar: Q1 Earnings Snapshot (Associated Press) -5.12%
07:00AM	Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update (GlobeNewswire)
Apr-30-26 04:05PM	Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's Ataxia (GlobeNewswire) -6.45%
Mar-19-26 07:22AM	Larimar: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-06-26 10:26AM	LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? (Zacks)
04:05PM	Loading…
Mar-04-26 04:05PM	Larimar Therapeutics to Participate in Upcoming Investor Conferences in March (GlobeNewswire)
08:50AM	Larimar Therapeutics price target raised to $12 from $11 at Wedbush (TipRanks)
Feb-25-26 08:59PM	Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering (GlobeNewswire) +61.25% -7.23%
04:01PM	Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering (GlobeNewswire)
02:30PM	Laminar Therapeutics Stock Is Popping Today: What's Going On? (Benzinga)
Feb-24-26 12:12PM	Larimar Therapeutics (LRMR) Surges On FDA Breakthrough Therapy Designation (Benzinga) +31.32%
07:00AM	Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026 (GlobeNewswire)
Dec-18-25 08:00AM	Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-05-25 07:14AM	Larimar: Q3 Earnings Snapshot (Associated Press Finance) -15.26%
07:00AM	Larimar Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat) -8.39%
Oct-09-25 04:14PM	Lost Money on Larimar Therapeutics, Inc. (LRMR)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile) -5.60%
Sep-29-25 07:00AM	Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -33.66%
Sep-28-25 05:00PM	Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire)
Aug-14-25 07:13AM	Larimar: Q2 Earnings Snapshot (Associated Press Finance) +14.52%
07:00AM	Loading…
07:00AM	Larimar Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-31-25 04:15PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-29-25 11:50PM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering (GlobeNewswire)
04:01PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
Jul-08-25 07:00AM	Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Jun-23-25 07:00AM	Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program (GlobeNewswire) -6.56%
Jun-20-25 04:05PM	Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia (GlobeNewswire) -5.47%
May-21-25 11:22AM	Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential (Insider Monkey) -6.31%
Apr-30-25 07:00AM	Larimar Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire) +10.88%
Apr-04-25 01:12PM	Larimar Therapeutics: Initiating Hold Rating With Upcoming Catalysts (Seeking Alpha)
Mar-24-25 07:00AM	Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -10.24%
Mar-03-25 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference (GlobeNewswire) -12.54% +5.28%
Jan-23-25 04:05PM	Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia (GlobeNewswire)
Dec-17-24 07:20AM	Larimar Therapeutics announces initial data from OLE study of nomlabofusp (TipRanks) -10.56%
Dec-16-24 07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study and Progress Across Nomlabofusp Program for Friedreich's Ataxia (GlobeNewswire) -21.72%
07:00AM	Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreichs Ataxia (GlobeNewswire)
Nov-18-24 07:00AM	Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024 (GlobeNewswire) -7.92%
Oct-30-24 07:00AM	Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results (GlobeNewswire) +8.74%
Sep-19-24 07:00AM	Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Aug-27-24 08:00AM	Larimar Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -6.54%
May-30-24 04:05PM	Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia (GlobeNewswire) +12.68%
May-22-24 11:25AM	Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study (Zacks)
May-21-24 07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) +8.53%
May-20-24 04:05PM	Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia (GlobeNewswire)
May-09-24 01:55PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results (GlobeNewswire)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
Mar-14-24 09:53PM	LRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.51%
05:32PM	Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:05PM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development (GlobeNewswire)
Mar-11-24 04:05PM	Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire) -15.39%
Mar-06-24 04:05PM	Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-20-24 01:47PM	Hedge Fund and Insider Trading News: Bill Ackman, George Soros, Arkhouse Management, TYR Capital, Borea Asset Management, Larimar Therapeutics, Inc. (LRMR), and More (Insider Monkey) -5.63%
Feb-19-24 01:48PM	Hedge Fund and Insider Trading News: Bill Ackman, David Tepper, Mark Yusko, Elliott Management, Conestoga Capital Advisors, Larimar Therapeutics Inc (LRMR), Agree Realty Corporation (ADC), and More (Insider Monkey)
Feb-16-24 04:20PM	Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -5.63%
Feb-14-24 06:15AM	Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock (GlobeNewswire) +36.84%
Feb-13-24 04:18PM	Larimar Therapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire) +11.62%
Feb-12-24 07:00AM	Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia (GlobeNewswire)
Nov-14-23 07:00AM	Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire) +7.11%
Nov-01-23 04:05PM	Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference (GlobeNewswire)
Oct-03-23 04:05PM	Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors (GlobeNewswire) -5.83%
Aug-31-23 04:05PM	Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference (GlobeNewswire)
Aug-10-23 07:00AM	Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results (GlobeNewswire)
Aug-07-23 09:22AM	Larimar Therapeutics Insiders Placed Bullish Bets Worth US$1.2m (Simply Wall St.) -7.19%
Jul-25-23 09:59AM	These 2 Strong Buy Penny Stocks Could Go Boom, Say Analysts (TipRanks) +7.67%
07:00AM	Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601s Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial (GlobeNewswire)
Jul-17-23 04:05PM	Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer (GlobeNewswire)
Jun-21-23 04:05PM	Larimar Therapeutics Set to Join Russell 3000® Index (GlobeNewswire)
May-15-23 07:00AM	Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trials 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreichs Ataxia and First Quarter 2023 Financial Results (GlobeNewswire) -29.05%
Mar-28-23 04:05PM	Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days (GlobeNewswire)
Mar-14-23 07:00AM	Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results (GlobeNewswire)
Feb-07-23 04:05PM	Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer (GlobeNewswire) +6.52% +7.99%
Nov-21-22 04:05PM	Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results (GlobeNewswire)
Nov-07-22 04:05PM	Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day (GlobeNewswire)
Oct-20-22 08:00AM	Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601 (GlobeNewswire)
Oct-19-22 04:05PM	Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research (GlobeNewswire)
Sep-16-22 01:00PM	Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares (GlobeNewswire) -5.04%
Sep-14-22 07:04AM	Larimar Therapeutics Announces $70 Million Underwritten Offering (GlobeNewswire) +15.56%
07:01AM	Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreichs Ataxia Patients (GlobeNewswire)
Aug-11-22 04:05PM	Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results (GlobeNewswire) +7.07%
Jul-28-22 04:05PM	Larimar Therapeutics Announces Presentation at the Upcoming Gordon Research Conference on Neurobiology of Brain Disorders (GlobeNewswire)
Jun-28-22 08:00AM	Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts (GlobeNewswire)
06:05AM	We're Keeping An Eye On Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Rate (Simply Wall St.)
Jun-02-22 08:00AM	Larimar Therapeutics Announces Upcoming Scientific Conference Presentations (GlobeNewswire)
May-19-22 08:00AM	Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinsons Disease and Movement Disorders Congress (GlobeNewswire)
May-12-22 07:00AM	Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results (GlobeNewswire) -7.91%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hamilton Thomas Edward	Director	Jul 06 '26	Buy	3.34	50,000	166,890	714,798	Jul 08 04:05 PM
Flynn James E	Director	Feb 27 '26	Buy	5.00	5,000,000	25,000,000	10,622,957	Mar 02 07:46 PM
Hamilton Thomas Edward	Director	Feb 27 '26	Buy	5.00	100,000	500,000	664,798	Mar 02 04:30 PM
THOMAS FRANK E	Director	Feb 27 '26	Buy	5.00	5,000	25,000	7,000	Mar 02 04:30 PM
SHERMAN JEFFREY W	Director	Feb 27 '26	Buy	5.00	5,000	25,000	5,000	Mar 02 04:30 PM

Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

CEO & DirectorDr. Carole S. Ben-Maimon M.D.

Secretary & CFOMr. Michael Celano CPA

Ph.D.Dr. Gopi Shankar M.B.A.

President & COOMr. John B. Harlow Jr.

Vice President of Finance & AdministrationMr. John Berman

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Larimar Therapeutics Inc

Upgrade your Finviz experience